Jason O’byrne Sells 1,634 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Jason O’byrne sold 1,634 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $9.53, for a total value of $15,572.02. Following the transaction, the chief financial officer owned 162,615 shares of the company’s stock, valued at $1,549,720.95. This trade represents a 0.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jason O’byrne also recently made the following trade(s):

• On Monday, February 23rd, Jason O’byrne sold 2,089 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total value of $15,563.05.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $9.09 on Friday. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -2.88 and a beta of 1.69. The business’s fifty day moving average price is $7.01 and its two-hundred day moving average price is $6.07. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.11. The company had revenue of $64.07 million for the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The firm’s revenue for the quarter was up 417.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.76) EPS. Research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Vir Biotechnology News Roundup

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas agreed to a collaboration on Vir’s prostate‑cancer asset (VIR‑5500) that includes up‑front and potential milestone payments totaling up to ~$1.7B, materially de‑risking that program and improving commercialization prospects. Read More.
• Positive Sentiment: Q4 results surprised to the upside: EPS and roughly $64M revenue beat consensus, signaling stronger commercial traction and likely underpinning recent analyst optimism. Read More.
• Positive Sentiment: Analysts have raised targets and ratings following the results and deal flow (Needham moved its target to $18), supporting upside from fundamentals despite volatility. Read More.
• Neutral Sentiment: Management will present at TD Cowen and Leerink in early March — useful for additional color and Q&A but not an immediate earnings/cash catalyst. Read More.
• Neutral Sentiment: Increased media/peer comparisons (head‑to‑head coverage) have raised visibility and trading volume; this can amplify moves but doesn’t change Vir’s underlying cashflow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross), which strengthens the balance sheet but is dilutive and increased near‑term share supply — a clear short‑term negative for the stock. Read More.
• Negative Sentiment: Market coverage singled out the discounted offering as the proximate cause of the post‑rally pullback, triggering selling and higher volatility. Read More.
• Negative Sentiment: Multiple insider sales were disclosed last week (including CEO and other senior officers/directors), increasing visible supply and feeding negative sentiment alongside the offering. Individual filings and summaries are available in SEC/insider reports. Read More.

Institutional Investors Weigh In On Vir Biotechnology

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after acquiring an additional 1,390 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Vir Biotechnology in the 3rd quarter worth $38,000. Raymond James Financial Inc. acquired a new stake in shares of Vir Biotechnology during the second quarter worth $35,000. UMB Bank n.a. increased its holdings in Vir Biotechnology by 1,418.7% in the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after purchasing an additional 6,597 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in Vir Biotechnology by 153.8% in the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after buying an additional 4,899 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on VIR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Evercore restated an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a research note on Tuesday. Needham & Company LLC lifted their price target on Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Tuesday, December 30th. Finally, Leerink Partners restated an “outperform” rating and issued a $20.00 price objective on shares of Vir Biotechnology in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.89.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.